Researchers found that circulating tumor cell counts stratified patients by disease aggressiveness and were associated with differing outcomes following endocrine versus combination therapy.
Research analyzing cell-free DNA fragmentation patterns in healthy individuals reveals physiological confounders that could improve test accuracy.
Coverage applies to stage II and III breast cancer patients across three major subtypes for up to six years of recurrence monitoring.
Research-use kit interrogates 84 genes using single-tube protocol, compatible with existing molecular laboratory equipment.
Read More
The deep learning system integrates dermoscopic images with patient metadata to improve diagnostic precision for skin cancer screening.
Read More
A screening tool aims to identify patients at high risk for cancer who may benefit from germline or hereditary DNA testing.
Read More
A simulation model shows that annual liquid biopsy screening would increase early-stage cancer detection by up to 30% while cutting stage IV diagnoses by 45%.
Read More
Research demonstrates 13% relative reduction in prostate cancer deaths but highlights overdiagnosis concerns, prompting calls for risk-based screening approaches.
Read More
The research‑use‑only test for post‑treatment breast cancer monitoring is now available through the company’s affiliate EG Biomed US.
Read More
University of Texas at Dallas researchers combine electrochemical biosensors with AI to identify volatile organic compounds linked to thoracic cancers.
Read More
Oncoguard Liver test demonstrates seven times greater sensitivity for very early-stage hepatocellular carcinoma compared to ultrasound surveillance.
Read More
TAPS+ chemistry preserves DNA integrity in challenging samples including FFPE tissue and circulating tumor DNA.
Read More
The test measures microRNA-371a-3P biomarker and can guide treatment decisions while reducing need for some CT scans during surveillance.
Read More
A new study demonstrates the capability of a blood test in detecting ovarian cancer up to three years prior to diagnosis in prospectively collected samples.Â
Read More
Circulating tumor DNA testing can identify stage 3 patients who may safely receive reduced treatment intensity, international study finds.
Read More
Self-collection for HPV and other infections offers a more convenient, private way to complete recommended screenings—helping reach women who might otherwise delay or skip care.
Read More
The mass spectrometry-based assay achieved 100% sensitivity in detecting patients who later progressed to cancer in a blinded cohort study.
Read More
A study of nearly 1,800 patients shows a threefold difference in sentinel node metastasis rates between high-risk and low-risk groups.
Read More